Frontier
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2012; 18(44): 6357-6375
Published online Nov 28, 2012. doi: 10.3748/wjg.v18.i44.6357
Table 3 Potential pharmacotherapy targets for intestinal failure
Dose mg/kg per dSide effectsStructureApproval
Growth hormone0.1Fluid retention, joint pain, hyperglycemia191-amino acid proteinFDA
EGFNA1NA53-amino acid peptideNot available commercially
GLP-20.1Abdominal pain/obstructive symptomsdpp-IV resistant 33-amino acid peptidePhase III clinical trials available in Europe